The risk of NODAT development in patients receiving no or low-dose EPO with an HbA1c ≥ 5.2% was 6.34-fold higher than in patients with an HbA1c < 5.2%, which is higher than the reported odds ratio of impaired glucose tolerance based on a OGTT [28]. Here, EPO is linked to Impaired glucose tolerance.